Home  |  About the Book  |  Table of Contents  |  Search  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurmasheva, R. T.
Right arrow Articles by Houghton, P. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kurmasheva, R. T.
Right arrow Articles by Houghton, P. J.

Combined Targeting of mTOR and the Insulin-like Growth Factor Pathway

Raushan T. Kurmasheva, PhD, John B. Easton, PhD, and Peter J. Houghton, PhD

From the Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, TN

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Address reprint requests to Peter J. Houghton, PhD, Department of Molecular Pharmacology, St. Jude Children's Research Hospital, 332 N. Lauderdale St., Memphis, TN 2794; e-mail: peter.houghton{at}stjude.org

Overview: Although conventional multimodality therapy is curative for most patients diagnosed with nonmetastatic rhabdomyosarcoma (RMS), the survival rate in children with metastatic disease has not improved significantly with the use of intensified therapy. With an increased understanding of the molecular pathogenesis of RMS, it is now possible to consider rational ideas to augmenting current therapies with molecularly targeted approaches. Here we consider the rationale for combining inhibitors of the serine/threonine kinase mTOR (mammalian target of rapamycin) with antibodies that inhibit the type 1 insulin-like growth factor receptor (IGF-1R).